

NEURAL ZOOMER *plus*

Neural Zoomer *plus*

Peptide level identification of neural sensitivity



1(866) 364-0963
support@vibrant-wellness.com



www.vibrant-wellness.com



1360 Bayport Ave. Ste. B
San Carlos, CA 94070

Final Report Date:	10-25-2018 18:44	Specimen Collected:	04-03-2018 12:44
Accession ID:	1512010000	Specimen Received:	04-04-2018 09:04

LAST NAME	FIRST NAME	MIDDLE NAME	GENDER	DATE OF BIRTH	ACCESSION ID
TESTNAME	PATIENT		MALE	2018-02-23	1512010000

PATIENT

Name: PATIENT TESTNAME
 Date of Birth: 2018-02-23
 Gender: Male
 Age: 0

Telephone #: 1-866-364-0963
 Street Address: 1021 HOWARD AVENUE SUITE B
 City: SAN CARLOS
 State: CA Zip #: 94070
 Email: fdu@vibrantsci.com

Fasting: FASTING No. of hours: 12.0
 EMR #: V1609100001
 Unique Patient #: A123456789

PROVIDER

Practice Name: Demo Client, MD
Provider Name: Demo Client, MD (999994)
 Phlebotomist:
 Street Address: 1234 TEST AVENUE
 City: TEST
 State: CA
 Zip #: 12345
 Telephone #: 1-800-842-7268
 Fax #:

For doctor's reference

Vibrant Wellness is pleased to present to you, 'Neural Zoomer Plus', to help you make healthy lifestyle and dietary choice in consultation with your healthcare provider. It is intended to be used as a tool to encourage a general state of health and well-being.

The Vibrant Neural Zoomer Plus is an array of neural antigens and genetic tests which offers very specific antibody-to-antigen recognition and potential risk to develop Neurological Autoimmune disease. The panel is designed to assess an individual's IgG, IgA and IgM sensitivity to these antigens at the peptide level. Neural Zoomer plus aims to reduce the prevalence of neurological conditions by empowering patients and physicians with a vital resource for early risk detection and an enhanced focus on personalized primary prevention.

Interpretation of Report: The test results of antibody levels to the individual proteins are calculated by comparing the average intensity of the individual protein antibody to that of a healthy reference population. Reference ranges have been established using 192 healthy individuals. The results are displayed as High Risk, Moderate or In Control. A high risk result indicates that you have an increased reactivity to the antigen with respect to the reference range. A Moderate sensitive result indicates that you have a moderate reactivity to the antigen with respect to the reference range. A Negative or In Control result indicates that you have a low reactivity to the antigen with respect to the reference range. Vibrant utilizes proprietary fluorescent analysis which is designed to assay specific total IgG (subclasses 1, 2, 3, 4), total IgA (subclasses 1, 2) and total IgM antibodies. The classification of High risk to Moderate to In Control denotes the level of antibody reactivity detected through this analysis.

The Vibrant Wellness platform provides tools for you to track and analyze your general wellness profile. Testing for Neural Zoomer + panel is performed by Vibrant America, a CLIA certified lab CLIA#:05D2078809. Vibrant Wellness provides and makes available this report and any related services pursuant to the Terms of Use Agreement (the "Terms") on its website at www.vibrant-wellness.com. By accessing, browsing, or otherwise using the report or website or any services, you acknowledge that you have read, understood, and agree to be bound by these terms. If you do not agree to accept these terms, you shall not access, browse, or use the report or website. The statements in this report have not been evaluated by the Food and Drug Administration and are only meant to be lifestyle choices for potential risk mitigation. Please consult your physician/dietitian for medication, treatment, or lifestyle management. This product is not intended to diagnose, treat, or cure any disease.


Please Note - It is important that you discuss any modifications to your diet, exercise and nutritional supplementation with your physician before making any changes. To schedule an appointment with Vibrant Clinical Dietitians please call: Toll-Free **866-364-0963**.

LAST NAME	FIRST NAME	MIDDLE NAME	GENDER	DATE OF BIRTH	ACCESSION ID
TESTNAME	PATIENT		MALE	2018-02-23	1512010000

INTRODUCTION

Autoimmunity is a main component in nervous system diseases where a misguided immune response attacks the body's own organs and tissues. Autoimmune disorders affect 5-10% of the general population and can target virtually any structure within the central or peripheral nervous system in a highly specific way, targeting a very specific cell population (e.g., Purkinje cells of the cerebellum). Depending on the cell type that is targeted in different central nervous system (CNS) structures (e.g., the astrocyte in neuromyelitis optica), the syndromes that result may be diverse, such as those associated with optic neuritis, myelitis, and attacks of brain edema in neuromyelitis optica.¹

Understanding these specific disorders requires an analysis of how the target antigen molecules affect immune cellular interactions both to generate the autoimmune reaction and to produce the immune-mediated injury of the nervous system. Autoantibodies are a novel emerging entity that is useful in providing such information in early stages of the disease with a simple blood sample. The Vibrant neurological autoimmune panel, "Neural Zoomer," includes a comprehensive spectrum of autoimmune markers responsible for a diverse range of neural autoimmune diseases that has the potential to provide the details of the specific type of autoimmune neural disease (eg: demyelination, blood brain barrier disruption, optical/peripheral neuropathy, neuromuscular disorders, brain inflammation and autoimmunity) and the degree of severity to implement the most effective treatment plan possible.



LAST NAME	FIRST NAME	MIDDLE NAME	GENDER	DATE OF BIRTH	ACCESSION ID
TESTNAME	PATIENT		MALE	2018-02-23	1512010000

Positive		Moderate		Negative			
(IgG + IgA)	IgM	(IgG + IgA)	IgM				
	Blood Brain Barrier Disruption Anti-s100b Peripheral Neuropathy Anti-GM1 Neuromuscular disorders Anti-Voltage gated potassium channels	Demyelination Antigens Anti-Tubulin Blood Brain Barrier Disruption Anti-s100b Anti-Glucose regulated protein 78 Brain Autoimmunity Anti-Amyloid beta (25-35)	Demyelination Antigens Anti-Myelin proteolipid protein Neuromuscular disorders Anti-Acetylcholine receptors Brain Autoimmunity Anti-RAGE peptide	Demyelination Antigens Anti-Myelin basic protein Anti-Myelin oligodendrocyte glycoprotein Anti-Neurofascin Anti-MAG Blood Brain Barrier Disruption Anti-Glial fibrillary acidic protein Anti-Microglia Optical and Autonomic nervous system disorder Anti-Neuron specific enolase Anti-Aquaporin4 Anti-Recoverin Anti-CV2 Peripheral Neuropathy Anti-GM2 Anti-Hu Anti-Ri Anti-Amphiphysin Neuromuscular disorders Anti-Muscle specific kinase Anti-Voltage gated calcium channels Anti-Titin Brain Autoimmunity Anti-HSV1 Anti-Cerebellum Anti-Purkinje cell Anti-Yo Anti-Amyloid beta (1-42) Anti-Tau Anti-Glutamate Anti-Dopamine Anti-Hydroxytryptamine Anti-Alpha-synuclein Anti-α1 and β2 adrenergic receptors Anti-Endothelin A receptor Anti-NMDA receptor Brain Inflammation Anti-AMPA receptor Anti-Dopamine receptor 1 Anti-Dopamine receptor 2 Anti-GABA receptors Anti-Dipeptidyl aminopeptidase like protein 6 Anti-Glycine receptor Anti-Neurexin 3 Anti-Contactin-Associated Protein-like 2 Antibodies Anti-Leucine-rich glioma-inactivated protein 1 (Anti-LG1) Anti-Ma Infection Anti-HSV2 Anti-EBV Anti-CMV Anti-HHV 6 Anti-HHV 7 Anti-Streptococcal A			

LAST NAME	FIRST NAME	MIDDLE NAME	GENDER	DATE OF BIRTH	ACCESSION ID
TESTNAME	PATIENT		MALE	2018-02-23	1512010000

LIFESTYLE CONSIDERATIONS

» Lifestyle Choices

- Treatments that rebuild and fortify a hyperpermeable intestinal barrier can aid in reversing or reducing autoimmune disease symptoms. Intestinal permeability syndrome is associated with autoimmune diseases and reversing symptoms of autoimmune diseases is accelerated with healing the lining of the gastrointestinal tract.⁵⁶ Vibrant's Wheat Zoomer can accurately detect the presence of intestinal permeability syndrome.
- Avoid exposure to heavy metals: Neurotoxicity of metals has been demonstrated widely. The CNS is particularly vulnerable to accumulation of these metals. The brain readily accumulates metals, which, under physiologic conditions, are incorporated into essential metalloproteins required for neuronal health and energy homeostasis. Severe consequences can arise from circumstances of excess essential metals or exposure to toxic nonessential metal.⁵⁷
- Avoid exposure to mold or high mold/water-damaged environments: Mold neurotoxicity is an increasingly common occurrence that can cause memory deficits, difficulty concentrating, problems with language and reasoning, mental fatigue, depression, and anxiety.⁵⁸
- Treat infections immediately: Herpes simplex virus type 2 (HSV-2) infection, for example, is responsible for significant neurological morbidity, perhaps more than any other virus. Research indicates that as many as 45 million people in the United States have been infected with HSV-2, and the estimated incidence of new infection is 1 million annually.⁴⁷
- Consider following programs that may help prevent and reverse the cognitive and physiological effects of neurological disorders, including but not limited to:
 - Bredesen's ReCODE (Reversal of Cognitive Decline) protocol⁵⁹, which is a comprehensive personalized program designed to improve cognition and reverse the cognitive decline of mild cognitive impairment, and early Alzheimer's disease.
 - The Wahls protocol
 - Hormone therapy⁶⁰
 - Physical therapy (e.g Mulligan technique, electrical stimulation)⁶¹⁻⁶³
 - Yoga⁶⁴
 - Instrument-assisted soft tissue mobilization (e.g.: cupping therapy)⁶⁵
 - Therapeutic taping (e.g.: Kinesiology taping)⁶⁶
 - Blood flow restriction therapy⁶⁷
 - Integrative dry needling⁶⁸

LAST NAME	FIRST NAME	MIDDLE NAME	GENDER	DATE OF BIRTH	ACCESSION ID
TESTNAME	PATIENT		MALE	2018-02-23	1512010000

LIFESTYLE CONSIDERATIONS

- Consider regular sauna bathing, as studies show high frequency of sauna use lowers the risk of dementia and Alzheimer's disease.⁶⁹
- Maintain a healthy lifestyle (healthy fat-rich and vegetable-heavy diet, omega-3-fatty acids, low sugar intake, quit smoking, regular exercise)⁷⁰
- Consider taking supplements: Research indicates inflammation and free radical oxidative stress play major roles in the propagation of neurodegenerative diseases. A few supplements in particular have been found to mitigate damage caused by oxidative stress and/or reduce the activity of TNF and other inflammatory cytokine pathways:
 - N-acetyl-L-cysteine (NAC) is a precursor to glutathione, the body's most important cellular antioxidant. NAC supplements have been shown to increase cellular glutathione levels.⁷¹
 - Vitamins B12, B6, and folate are metabolic cofactors important for cellular metabolism and maintenance of all tissue cell types, but particularly important to nerve cells. Deficiencies in B12 or folate can raise homocysteine levels, which have been associated with a higher risk for vascular disease and dementia.⁷²
 - B12 absorption from the intestine tends to diminish with age. B12 deficiency can damage the nervous system leading to neuropathy, myelopathy, and dementia.⁷³
 - Alpha Lipoic Acid (ALA) is an essential cofactor in normal cellular metabolism and cellular energy production. The use of ALA as a supplement is under investigation, and has demonstrated improvements in peripheral neuropathy, Alzheimer's disease, and insulin-resistant type II diabetes.⁷⁴
 - Vitamin C and vitamin E supplements can reverse symptoms caused by vitamin C and E deficiencies.⁷⁵

LAST NAME	FIRST NAME	MIDDLE NAME	GENDER	DATE OF BIRTH	ACCESSION ID
TESTNAME	PATIENT		MALE	2018-02-23	1512010000

Demyelination Antigens

Anti-Tubulin

Tubulin is a 55 kDa cytoplasm globular protein expressed in blood, nervous, secretory, reproductive, musculoskeletal and other internal cells. Anti-tubulin is associated with alcoholic liver disease, demyelinating disease, Grave's disease, Hashimoto's thyroiditis, infectious agent exposure PANDAS/ANDAS/OCD, rheumatoid arthritis, and recent onset type 1 diabetes.²

	Current Result	Previous Result	Reference Range
(IgG + IgA)	6.1 -	6.4 -	≤10.0
IgM	10.3 ⚠	16.8 ⚠	≤10.0

Anti-Myelin basic protein

Myelin basic protein (MBP) is a protein believed to be important in the process of myelination of nerves in the nervous system. Anti-Myelin basic protein is related to the risk for multiple sclerosis, autism, PANDAS/ANDAS/OCD, and systemic lupus erythematosus (SLE).³

	Current Result	Previous Result	Reference Range
(IgG + IgA)	6.0 -	6.2 -	≤10.0
IgM	0.9 -	7.3 -	≤10.0

Anti-Myelin oligodendrocyte glycoprotein

Myelin oligodendrocyte glycoprotein (MOG) is a glycoprotein associated with the myelination of nerves in the central nervous system (CNS). Antibodies against MOG are found in various demyelinating diseases, including multiple sclerosis, neuromyelitis optica spectrum disorders (NMOSD), idiopathic optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), multiphasic disseminated encephalomyelitis (MDEM), Devic's disease, and tumefactive demyelinating disease.⁴

	Current Result	Previous Result	Reference Range
(IgG + IgA)	0.5 -	6.6 -	≤10.0
IgM	5.0 -	4.1 -	≤10.0

Anti-Myelin proteolipid protein

Myelin proteolipid protein (PLP) is the major membrane protein of CNS myelin and its expression is largely limited to oligodendrocytes.⁵ Anti-PLP is a useful marker in patients with seronegative anti-myelin basic protein, the frequent marker in active multiple sclerosis and optic neuritis.⁶⁻⁷

	Current Result	Previous Result	Reference Range
(IgG + IgA)	18.7 ⚠	2.9 -	≤10.0
IgM	5.4 -	>30.0 +	≤10.0

LAST NAME	FIRST NAME	MIDDLE NAME	GENDER	DATE OF BIRTH	ACCESSION ID
TESTNAME	PATIENT		MALE	2018-02-23	1512010000

Anti-Neurofascin

Neurofascin (NF), a cell adhesion molecule expressed in both the CNS and the peripheral nervous system (PNS), plays important roles in developing and maintaining neural structures. Anti-neurofascin autoantibodies are found mainly in combined central and peripheral demyelination (CCPD), a rare demyelinating condition affecting both CNS and peripheral nervous system (PNS) tissues⁸, and also in chronic inflammatory demyelinating polyneuropathy (CIDP)⁹ and axonal injury in patients with multiple sclerosis (MS).¹⁰ Recognition of this antibody may be important in treatment management, because anti-neurofascin seropositive CCPD patients respond well to Intravenous Immunoglobulin or plasma exchange treatments.¹¹



Anti-MAG

Myelin-associated glycoprotein (MAG) is a trans-membrane protein of both the CNS and peripheral nervous system (PNS) myelin, involved in the process of myelination. Anti-MAG peripheral neuropathy is a very rare disease caused by anti-MAG antibodies that destroy MAG protein leading to disruptions of normal myelin production and healthy peripheral nerve activity.¹²



Blood Brain Barrier Disruption


Anti-s100b

S100B is a calcium-binding protein produced mainly by astrocytes. This protein is localized in the cytoplasm and nucleus of a wide range of cells and involved in the regulation of several cellular processes such as cell cycle progression and differentiation. Studies have shown extravasated S100B may trigger a pathologic autoimmune reaction linking systemic and CNS immune responses.¹³



Anti-Glial fibrillary acidic protein

Glial fibrillary acidic protein (GFAP) is the major structural protein of the glial intermediate filament of astrocytes that forms part of the cytoskeleton of mature astrocytes and other glial cells, but is not found outside the CNS. Anti-GFAP is produced when the protein enters the bloodstream after a rupture of the blood brain barrier, thus serves as a blood based diagnostic marker of brain injury.¹⁴



LAST NAME	FIRST NAME	MIDDLE NAME	GENDER	DATE OF BIRTH	ACCESSION ID
TESTNAME	PATIENT		MALE	2018-02-23	1512010000

Anti-Microglia

Microglia are a type of macrophage located throughout the brain and spinal cord that act as the first and main form of active immune defense in the CNS. These markers indicate a destruction of the blood brain barrier and are found to play a role in tissue destruction of Alzheimer's disease.¹⁴

	Current Result	Previous Result	Reference Range
(IgG + IgA)	2.2 -	>30.0 +	≤10.0
IgM	2.2 -	9.0 -	≤10.0

Anti-Glucose regulated protein 78

Glucose regulated protein 78 (GRP78) is a major endoplasmic reticulum (ER) chaperone protein critical for protein quality control of the ER, as well as controlling the activation of the ER-transmembrane signaling molecules. Studies show that antibodies targeting glucose-regulated protein 78 are able to activate brain microvascular endothelial cells and induce protein extravasation in cell lines and in mice with neuromyelitis optica. Thus, these findings suggest that glucose-regulated protein 78-targeted antibodies could instigate blood brain barrier breakdown and development of hallmark anti-aquaporin-4 autoantibody pathology. Therefore, the application of these antibodies may be useful to disrupt the blood brain barrier for transit of treatments for many CNS diseases.¹⁵

	Current Result	Previous Result	Reference Range
(IgG + IgA)	4.1 -	5.9 -	≤10.0
IgM	15.7 ▽	7.5 -	≤10.0

Optical and Autonomic Nervous System Disorders

Anti-Neuron specific enolase

Neuron specific enolase is a protein enzyme that is encoded by the ENO2 gene. It is found in mature neurons and cells of neuronal origin. Antibodies against neuron specific enolase are found in patients with optical neuropathies.

	Current Result	Previous Result	Reference Range
(IgG + IgA)	9.2 -	8.9 -	≤10.0
IgM	5.8 -	3.8 -	≤10.0

Anti-Aquaporin 4

Neuromyelitis optica is an inflammatory demyelinating disorder of the CNS. The discovery of circulating IgG antibodies against the astrocyte water channel protein aquaporin 4 (AQP4) and the evidence that AQP4-IgG is involved in the development of neuromyelitis optica revolutionized the understanding of the disease. Anti-aquaporin 4 antibodies have also been shown in patients with peripheral demyelination. In addition, human aquaporin 4 shows cross-reactivity with corn and soybean aquaporins,¹⁷ hence, consider ordering Vibrant's Lectin Zoomer panel for a comprehensive assessment.

	Current Result	Previous Result	Reference Range
(IgG + IgA)	9.1 -	8.8 -	≤10.0
IgM	4.7 -	2.7 -	≤10.0

LAST NAME	FIRST NAME	MIDDLE NAME	GENDER	DATE OF BIRTH	ACCESSION ID
TESTNAME	PATIENT		MALE	2018-02-23	1512010000

Anti-Recoverin

Anti-recoverin antibodies are one of the key components of antibody disorders of the CNS. They have also been shown to be associated with retinopathy, which is characterized by impaired vision and photosensitivity.



Anti-CV2

Anti-CV2 antibodies are a group of antibodies that react with a 66-kd brain protein belonging to the family of CRMP proteins. The manifestations associated with anti-CV2 antibodies include cerebellar degeneration, uveitis, and peripheral neuropathy, and mixed axonal and demyelinating peripheral neuropathy.¹⁸



Peripheral Neuropathy


Anti-GM1

Detection of ganglioside M1 (GM1) antibodies, usually of the IgM isotype, is associated with multi-focal motor neuropathy and lower motor neuropathy, characterized by muscle weakness and atrophy. Multi-focal motor neuropathy may occur with or without high serum titers of anti-GM1 antibodies. GM1 antibodies are detected in approximately 50% of persons with multi-focal motor neuropathy.



Anti-GM2

GM2 ganglioside is a potential peripheral nerve antigen for neuropathy-associated autoantibodies. Anti-GM2 IgM antibodies have been reported in some patients with dysimmune neuropathy or lower motor neuron syndrome, in whom they were often associated with a concomitant reactivity with GM1.



LAST NAME	FIRST NAME	MIDDLE NAME	GENDER	DATE OF BIRTH	ACCESSION ID
TESTNAME	PATIENT		MALE	2018-02-23	1512010000

Anti-Hu

The anti-Hu antibody is the most frequent manifestation of sensory neuropathy with frequent autonomic involvement. The clinical patterns of the neuropathies is in keeping with accordance with the cellular distribution of the HuD antigen.



Anti-Ri

Anti-Ri has been reported in serum and cerebrospinal fluid (CSF) of patients who present typically with a subacute neurological disorder involving the brainstem, cerebellum, and spinal cord. This antigen is also found in a rare disorder known as opsoclonus/myoclonus syndrome.¹⁹



Anti-Amphiphysin

Amphiphysin is a non-intrinsic membrane protein that is concentrated in nerve terminals. The serum of patients with stiff-person syndrome often contain antibodies to this protein. Stiff-person syndrome (SPS) is a neurological disorder characterized by progressive muscle stiffness (rigidity) and repeated episodes of painful muscle spasms.



Neuromuscular disorders

Anti-Acetylcholine receptors

Acetylcholine receptors are responsible for binding acetylcholine, a neurotransmitter for signal transduction in CNS. They are localized in neuromuscular junctions. Antibodies against acetylcholine receptor are found in myasthenia gravis disease, which destroys the receptor function, leading to a neuromuscular transmission defect, which then causes hypofunction, fatigue, and inflammation of skeletal muscles and produces serum antibodies against muscle antigens.²⁰



LAST NAME	FIRST NAME	MIDDLE NAME	GENDER	DATE OF BIRTH	ACCESSION ID
TESTNAME	PATIENT		MALE	2018-02-23	1512010000

Anti-Muscle specific kinase

Muscle-specific kinase (MuSK) is a single-pass transmembrane protein that has a critical role in signaling between motor neurons and skeletal muscle. Anti-MuSK is an important marker in patients without anti-acetylcholine receptor antibodies in myasthenia gravis disease.²¹

	Current Result	Previous Result	Reference Range
(IgG + IgA) 	1.5 	3.6 	≤10.0
IgM 	1.1 	8.3 	≤10.0


Anti-Voltage gated calcium channels

Voltage-gated calcium channels (VGCCs) are a group of voltage-gated ion channels found in the membrane of excitable cells such as muscle, glial cells, and neurons. They are key transducers of membrane potential changes into intracellular Ca²⁺ transients that initiate many physiological events. In neurons, voltage-gated Ca²⁺ channels initiate synaptic transmission. Anti-voltage-gated calcium channel autoantibodies are responsible for Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder of the neuromuscular junction.²²

	Current Result	Previous Result	Reference Range
(IgG + IgA) 	2.3 	9.5 	≤10.0
IgM 	8.5 	5.6 	≤10.0





Anti-Voltage gated potassium channels

Voltage-gated potassium channels (Kv) play a vital role in a variety of cellular processes, including the functioning of excitable cells, regulation of apoptosis, cell growth and differentiation, the release of neurotransmitters and hormones, and maintenance of cardiac activity. They are found along the axon and at the synapse of the neurons, to propagate electrical signals. In neuromyotonia, the anti-voltage-gated potassium channel autoantibodies downregulate the potassium channels expressed on the peripheral nerve terminal leading to nerve hyperexcitability.²²

	Current Result	Previous Result	Reference Range
(IgG + IgA) 	28.5 	9.2 	≤10.0
IgM 	0.2 	17.5 	≤10.0

Anti-Titin

Titin, also known as connectin, is a flexible filamentous protein, which is the largest protein known today. Titin is known to be important for myofibrillogenesis, sarcomere structure, and elasticity. Anti-titin antibodies are present in 70–90% of thymoma autoimmune myasthenia gravis (MG) patients, and in approximately 50% of late-onset acetylcholine-MG patients without thymoma. In general, anti-titin antibodies correlate with disease severity and may identify patients more likely to be refractory to therapy, including thymectomy.²³

	Current Result	Previous Result	Reference Range
(IgG + IgA) 	3.8 	0.7 	≤10.0
IgM 	8.8 	1.8 	≤10.0

LAST NAME	FIRST NAME	MIDDLE NAME	GENDER	DATE OF BIRTH	ACCESSION ID
TESTNAME	PATIENT		MALE	2018-02-23	1512010000

Brain Autoimmunity

Anti- Cerebellum

The cerebellum is a region of the brain that plays an important role in motor control. The cerebellum does not initiate movement, but contributes to coordination, precision, and accurate timing. It receives input from sensory systems of the spinal cord and from other parts of the brain and integrates these inputs to fine-tune motor activity. Cerebellar damage produces disorders in fine movement, equilibrium, posture, and motor learning. Anti-cerebellum antibodies implicates a possible damage to the cerebellum that could lead to ataxia.²⁴ In addition, these antibodies are associated with disorders like autism and may be useful as markers for specific behavioral characteristics of autism.²⁵

	Current Result	Previous Result	Reference Range
(IgG + IgA)	8.6 -	24.2 +	≤10.0
IgM	6.8 -	4.9 -	≤10.0

Anti-Purkinje cell

Purkinje cells, or Purkinje neurons, are a class of GABAergic neurons located in the cerebellum. Purkinje cells are aligned like dominos stacked one in front of the other. Their large dendritic arbors form nearly two-dimensional layers through which parallel fibers from the deeper-layers pass.

	Current Result	Previous Result	Reference Range
(IgG + IgA)	4.8 -	5.2 -	≤10.0
IgM	5.8 -	25.8 +	≤10.0

Anti-Yo

Anti-Yo antibodies are found in the serum of patients with neurologic paraneoplastic syndromes and reported to have activity against Purkinje cells of the cerebellum. They are found in ataxic syndrome, which is the most common variant of paraneoplastic cerebellar degeneration (PCD).²⁶

	Current Result	Previous Result	Reference Range
(IgG + IgA)	4.3 -	4.8 -	≤10.0
IgM	3.8 -	6.3 -	≤10.0

Anti-Amyloid beta (25-35)

A β is the cleavage product of the transmembrane amyloid- β precursor protein (APP). Major species of A β are A β 40 and A β 42, containing 40 and 42 amino acids, respectively. Although the pathogenesis of Alzheimer's disease (AD) is not fully understood, it is widely accepted that accumulation of A β in the brain, especially the more amyloidogenic A β 42, due to overproduction (familial AD) or impaired clearance (sporadic AD) initiates the pathogenic cascade, ultimately leading to neurodegeneration and dementia. The levels of autoantibodies reacting with oligomers of a short but neurotoxic fragment of A β , A β (25-35), were significantly higher in AD patients than in the control group who had undetectable autoantibodies to the A β fragment.

	Current Result	Previous Result	Reference Range
(IgG + IgA)	3.2 -	6.4 -	≤10.0
IgM	14.0 V	7.2 -	≤10.0

LAST NAME	FIRST NAME	MIDDLE NAME	GENDER	DATE OF BIRTH	ACCESSION ID
TESTNAME	PATIENT		MALE	2018-02-23	1512010000

Anti-Amyloid beta (1-42)

Beta-amyloid is a subunit of a larger protein called amyloid precursor protein (APP). APP extends from the inside of brain cells to the outside by passing through the fatty membrane around the cell. When APP is activated, it is cleaved to two different subunits, a chain containing 40 amino acids (the main form), and a chain containing 42 amino acids (amyloid beta 1-42). Amyloid-beta is one of the signature markers in Alzheimer's disease (AD). According to the "amyloid cascade hypothesis" that has been a cornerstone of the AD etiology for the last 20 years, the amyloid-beta deposition in the brain precipitates the formation of neurofibrillary tangles (NFTs).²⁷



Anti-RAGE peptide

The receptor for advanced glycosylation end products (RAGE) has been identified as the major receptor at the blood brain barrier to mediate the flux of amyloid- β protein ($A\beta$) from the blood to the brain. The anti-RAGE antibodies were found in Alzheimer's disease patients. In addition, studies demonstrated that they were significantly higher in Alzheimer's disease patients with diabetes.²⁸



Anti-Tau

Tau protein is found in the neurofibrillary tangles in brains of individuals who have Alzheimer's disease. Studies have shown that antibodies to the tau protein have been found in a number of AD patients when compared to healthy subjects. Other studies have also indicated that the levels of antibodies to tau are increased in patients with multiple sclerosis.



Anti-Glutamate

Glutamate is the major excitatory neurotransmitter of the CNS and it is crucially needed for numerous key neuronal functions. These autoimmune anti-glutamate antibodies can bind neurons in a few brain regions, activate glutamate receptors, decrease glutamate receptor expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, and induce behavioral/psychiatric/cognitive abnormalities and ataxia. Most of these autoantibodies are found in epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke.²⁹



LAST NAME	FIRST NAME	MIDDLE NAME	GENDER	DATE OF BIRTH	ACCESSION ID
TESTNAME	PATIENT		MALE	2018-02-23	1512010000


Anti-Dopamine

Dopamine is a crucial neurotransmitter in the brain and dopaminergic dysfunction is thought to underlie common human diseases, such as Parkinson's disease, Tourette's syndrome, and schizophrenia. Anti-dopamine antibody positive patients with encephalitis were found to have movement disorders characterized by parkinsonism, dystonia, and Sydenham chorea.³⁰



Anti-Hydroxytryptamine

Serotonin (5-hydroxytryptamine, 5-HT) is one of the most extensively studied neurotransmitters of the CNS. These autoantibodies are found mainly in autoimmune encephalitis.³¹



Anti-Alpha-synuclein

Alpha-synuclein is a presynaptic neuronal protein that is linked genetically and neuropathologically to Parkinson's disease. Anti-Alpha-synuclein autoantibodies are mainly elevated in Parkinson's disease and Alzheimer's disease.³²



Anti-α1 and β2 adrenergic receptors

The adrenergic receptors (α1 and β2 adrenergic receptors) are a class of G protein-coupled receptors that are targets of many catecholamine neurotransmitters like norepinephrine (noradrenaline) and epinephrine (adrenaline). The anti-α1 and β2 adrenergic receptors were found mainly in patients with different dementia forms such as unclassified, Lewy body, vascular and Alzheimer's dementia.³³



Anti-Endothelin A receptor

Endothelin peptides modulate the development of distinct neural cell types including Schwann cells, astrocytes, and neural crest cells as well as physiologic renal growth and development. The endothelin A receptor has a greater affinity for ET-1, one of the peptides of endothelin. The endothelin A receptor autoantibodies are found in vascular dementia.³⁴



LAST NAME	FIRST NAME	MIDDLE NAME	GENDER	DATE OF BIRTH	ACCESSION ID
TESTNAME	PATIENT		MALE	2018-02-23	1512010000

Brain Inflammation


Anti-NMDA receptor

N-methyl-D-aspartate (NMDA) is an amino acid derivative very similar to glutamate. Because glutamate is the excitatory neurotransmitter found in most synapses of the central nervous system, pharmacologists made this analogue called NMDA to activate a sub-type of glutamate receptors. Anti-NMDA receptor encephalitis, first identified in 2007, is an autoimmune disease that occurs when antibodies turn on the brain and cause it to swell.³⁵ Anti-NMDA receptor and anti-dsDNA, a major contributor in systemic lupus disease, share a common pentapeptide sequence, thus making them candidates for cross-reactivity.³⁶ Consider ordering Vibrant's Connective Tissue Disorder panel for the most comprehensive assessment.



Anti-Dopamine receptor 1

Dopamine receptor 1 (DR1) expression in the central nervous system is highest in the dorsal striatum and ventral striatum. DR1 is the most abundant dopamine receptor in the central nervous system. It regulates neuronal growth and development, mediates some behavioral responses, and modulates dopamine receptor 2-mediated events. Antibodies associated with DR1 are mostly seen in brain inflammation and neuropsychiatric disorders.³⁸




Anti-Dopamine receptor 2

Similar to dopamine receptor 1, dopamine receptor 2 (DR2) is highly expressed in basal ganglia, for example striatum, but also in the cortex, hippocampus, and substantia nigra. Modulation of DR2 expression in the basal ganglia has been associated with schizophrenia, depression, and movement disorders. Movement and psychiatric disorders associated with DR2 antibody are biologically plausible as DR2 is intimately linked to the control of movement and behavior.³⁰



Anti-GABA receptors

Gamma-Amino Butyric acid (GABA) is an amino acid which acts as a neurotransmitter in the CNS. It inhibits nerve transmission in the brain, calming nervous activity. Temporal lobe epilepsy (TLE), Parkinson's disease (PD) and Huntington's disease (HD) are neurodegenerative disorders that involve disruptions in gamma-amino butyric acid (GABA) signaling.³⁹



LAST NAME	FIRST NAME	MIDDLE NAME	GENDER	DATE OF BIRTH	ACCESSION ID
TESTNAME	PATIENT		MALE	2018-02-23	1512010000

Anti-Dipeptidyl aminopeptidase-like protein 6

Dipeptidyl aminopeptidase-like protein 6 is a protein that in humans is encoded by the DPP6 gene. This gene encodes a single-pass type II membrane protein that is a member of the S9B family in clan SC of the serine proteases. Antibodies against dipeptidyl-peptidase-like protein-6 (DPPX), an auxiliary subunit of Kv4.2 potassium channels involved in signal transduction, were identified in 7 patients with encephalitis.⁴⁰



Anti-Glycine receptor

Glycine accomplishes several functions as a transmitter in the CNS. As an inhibitory neurotransmitter, it participates in the processing of motor and sensory information that permits movement, vision, and audition. This action of glycine is mediated by the strychnine-sensitive glycine receptor, whose activation produces inhibitory post-synaptic potentials. Detection of glycine receptor antibodies may prove helpful in the diagnosis of patients with symptoms and signs that include ocular motor and other brainstem dysfunction, hyperekplexia, stiffness, rigidity, myoclonus and spasms, and their detection will support the use of immunotherapies that are likely to be clinically effective.⁴¹



Anti-Neurexin 3

Neurexin is a presynaptic protein that helps to connect neurons at the synapse. They are located mostly on the presynaptic membrane and contain a single transmembrane domain. Neurexin-3α autoantibodies associate with a severe but potentially treatable encephalitis in which the antibodies cause a decrease of neurexin-3α and alter synapse development.⁴²



Anti-Contactin-associated protein-like 2 antibodies

CNTNAP2 (Contactin-associated protein-like 2) is a protein coding gene. This gene encodes a member of the neurexin family which functions in the vertebrate nervous system as cell adhesion molecules and receptors. Diseases associated with CNTNAP2 include Pitt-Hopkins-Like Syndrome 1 and Autism 15. Among its related pathways are neuroscience and cell adhesion molecules (CAMs).⁴³



LAST NAME	FIRST NAME	MIDDLE NAME	GENDER	DATE OF BIRTH	ACCESSION ID
TESTNAME	PATIENT		MALE	2018-02-23	1512010000

Anti-Leucine-rich glioma-inactivated protein (Anti-LGI1)

The leucine-rich glioma inactivated-1 gene is rearranged as a result of translocations in glioblastoma cell lines. The protein contains a hydrophobic segment representing a putative transmembrane domain with the amino terminus located outside the cell. It also contains leucine-rich repeats with conserved cysteine-rich flanking sequences. This gene is predominantly expressed in neural tissues and its expression is reduced in low grade brain tumors and significantly reduced or absent in malignant gliomas. LGI1 antibody-associated encephalitis has increasingly been recognized as a primary autoimmune disorder.⁴⁴

	Current Result	Previous Result	Reference Range
(IgG + IgA)	7.4	2.2	≤10.0
IgM	4.6	4.6	≤10.0

Anti-Ma

Anti-Ma antibodies recognize Ma family proteins, which are exclusively found in neurons and testicular germ cells. Anti-Ma antibodies are found in patients with a wide range of neurological syndromes including limbic encephalitis (LE), diencephalic encephalitis (DE), or brainstem encephalitis (BE).⁴⁵

	Current Result	Previous Result	Reference Range
(IgG + IgA)	3.4	4.9	≤10.0
IgM	2.3	5.3	≤10.0

Infections

Anti-HSV-1

Herpes simplex virus 1 (HSV-1) is a member of the herpesvirus family, Herpesviridae, that infect humans. HSV-1 (which produces most cold sores) is ubiquitous and contagious. As a neurotropic and neuroinvasive virus, HSV-1 persists in the body by becoming latent and hiding from the immune system in the cell bodies of neurons. HSV-1 has been reported to have a pathogenesis role in Herpes simplex encephalitis (HSE) and seropositivity to HSV-1 antibodies has been correlated with increased risk of Alzheimer's disease.⁴⁶

	Current Result	Previous Result	Reference Range
(IgG + IgA)	2.4	6.7	≤10.0
IgM	4.3	2.5	≤10.0

Anti-HSV-2

Herpes simplex virus type 2 (HSV-2)-associated neurological disease may result from primary infection or reactivation of latent HSV-2. Herpes simplex encephalitis (HSE) is a disorder commonly associated with HSV-2. HSE due to HSV-2 may occur without meningitis features. Antibodies against HSV-2 have shown positive correlation in patients with symptoms of HSE.⁴⁷

	Current Result	Previous Result	Reference Range
(IgG + IgA)	5.0	8.8	≤10.0
IgM	8.9	6.8	≤10.0

LAST NAME	FIRST NAME	MIDDLE NAME	GENDER	DATE OF BIRTH	ACCESSION ID
TESTNAME	PATIENT		MALE	2018-02-23	1512010000

Anti-EBV

Central nervous system (CNS) complications of Epstein-Barr virus (EBV) infection occur in up to 18% of patients with infectious mononucleosis and include encephalitis, meningitis, and psychiatric abnormalities.⁴⁸ Antibodies against the EBV nuclear antigen complex (EBNAc) and EBNA-1 have been correlated with increased risk of multiple sclerosis (MS). The role of EBV in the pathogenesis of multiple sclerosis was attributed to molecular mimicry between EBV and central nervous system (CNS) antigen, myelin basic protein (MBP).⁴⁹

	Current Result	Previous Result	Reference Range
(IgG + IgA)	1.1	0.7	≤10.0
IgM	5.9	8.9	≤10.0

Anti-CMV

Cytomegalovirus (CMV) infections have been reported frequently to be associated with Guillain-Barre syndrome (GBS). In GBS, anti-GM2 antibodies have been detected in 22-67% of CMV-infected patients. Studies showed that anti-ganglioside antibodies that can bind to peripheral nerves and interfere with neuromuscular transmission in CMV-infected GBS patients are induced by molecular mimicry between GM2 and antigens that are induced by a CMV infection.⁵⁰⁻⁵¹

	Current Result	Previous Result	Reference Range
(IgG + IgA)	3.5	5.5	≤10.0
IgM	0.5	0.1	≤10.0

Anti-HHV-6

Human herpesvirus-6 (HHV-6) is frequently associated with neurologic diseases, including multiple sclerosis (MS), epilepsy, encephalitis, and febrile illness. This ubiquitous β -herpesvirus exists in two variants that share 95% sequence homology, HHV-6A and HHV-6B. The identical sequence homology was found between human herpesvirus-6 and myelin basic protein (MBP), one of the autoantigens implicated in MS pathology. High HHV-6 antibody titers were found in MS patients, implicating its role in MS.⁵² Apart from MS, studies have shown increased HHV-6A in multiple brain regions in Alzheimer's disease (AD) patients implicating a potential neuropathological role in AD.^{46, 53}

	Current Result	Previous Result	Reference Range
(IgG + IgA)	1.7	1.4	≤10.0
IgM	0.2	9.0	≤10.0

Anti-HHV-7

HHV-7 has been less frequently associated with CNS disease than HHV-6, but found to be associated with encephalitis, meningitis, and demyelinating conditions. Similar to HHV 6A, increased levels of HHV-7 were found in multiple brain regions in Alzheimer's disease (AD) patients.^{46, 53}

	Current Result	Previous Result	Reference Range
(IgG + IgA)	1.0	2.5	≤10.0
IgM	0.3	4.7	≤10.0

LAST NAME	FIRST NAME	MIDDLE NAME	GENDER	DATE OF BIRTH	ACCESSION ID
TESTNAME	PATIENT		MALE	2018-02-23	1512010000

Anti-Streptococcal A

Group A beta-haemolytic streptococcal (GABHS) tonsillitis, more frequently known as streptococcal pharyngitis, is highly prevalent in children, especially in those who are between the ages of 5 and 15 years. A subset of these children may develop PANDAS characterized by pediatric obsessive-compulsive disorder (OCD) and tic disorder, and Sydenham Chorea. Anti-streptococcal A antibodies are shown to cross react with different brain proteins that could lead to neuropsychiatric symptoms.⁵⁴



Key Terms/Glossary

Acute disseminated encephalomyelitis

Acute disseminated encephalomyelitis (ADEM) is characterized by a brief but widespread attack of inflammation in the brain and spinal cord that damages myelin, the protective covering of nerve fibers.

Alzheimer's disease

Alzheimer's disease is the most common cause of dementia, a group of brain disorders that cause the loss of intellectual and social skills.

Aquaporin

Aquaporins are membrane water channels that play critical roles in controlling the water contents of cells.

Ataxia

Ataxia is typically defined as the presence of abnormal, uncoordinated movements.

Cerebellar ataxia

Cerebellar ataxia is a disorder that occurs when the cerebellum becomes inflamed or damaged. The cerebellum is the area of the brain responsible for controlling gait and muscle coordination.

Chronic inflammatory demyelinating polyneuropathy

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms.

Demyelinating disease

A demyelinating disease is any disease of the nervous system in which the myelin sheath of neurons is damaged. This damage impairs the conduction of signals in the affected nerves.

Encephalitis

Encephalitis is an inflammation of the brain.

Epilepsy

Epilepsy is a CNS (neurological) disorder in which brain activity becomes abnormal, causing seizures or periods of unusual behavior, sensations, and sometimes loss of awareness.

Graves' disease

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactive thyroid.

Key Terms/Glossary

Gynecological cancers

Gynecologic cancer is an uncontrolled growth and spread of abnormal cells that originate from the reproductive organs.

Hashimoto's thyroiditis

Hashimoto's disease is an autoimmune disorder that can cause hypothyroidism, or underactive thyroid.

Huntington's disease

Huntington's disease is an inherited disease that causes the progressive breakdown (degeneration) of nerve cells in the brain.

Multi-focal motor neuropathy

Multifocal motor neuropathy (MMN) is a rare neuropathy characterized by progressive, asymmetric muscle weakness and atrophy (wasting).

Multiple sclerosis

Multiple sclerosis (MS) involves an immune-mediated process in which an abnormal response of the body's immune system is directed against the CNS.

Myasthenia gravis

Myasthenia gravis (MG) is a neuromuscular disorder that causes weakness in the skeletal muscles, which are the muscles your body uses for movement.

Myelination

Myelination is a term in anatomy that is defined as the process of forming a myelin sheath around a nerve to allow nerve impulses to move more quickly.

Neuromyelitis optica

Neuromyelitis optica (NMO), also known as Devic's disease or Devic's syndrome, is a heterogeneous condition consisting of the inflammation and demyelination of the optic nerve (optic neuritis) and the spinal cord (myelitis).

Neuromyotonia

Neuromyotonia (NMT) is a form of peripheral nerve hyperexcitability that causes spontaneous muscular activity resulting from repetitive motor unit action potentials of peripheral origin.

OCD

Obsessive-compulsive disorder (OCD) is an anxiety disorder characterized by recurrent and disturbing thoughts (called obsessions) and/or repetitive, ritualized behaviors that the person feels driven to perform (called compulsions).

Key Terms/Glossary

Oligodendrocytes

Oligodendrocytes are the myelinating cells of the CNS.

PANDAS

PANDAS is short for Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections.

Paraneoplastic opsoclonus /myoclonus syndrome

Paraneoplastic opsoclonus-myoclonus syndrome (OMS) is a rare complication of cancer characterized by chaotic, synchronous eye movements (opsoclonus), spontaneous muscle jerks (myoclonus), and ataxia.

Parkinson's disease

Parkinson's disease is a progressive nervous system disorder that affects movement.

Peripheral neuropathy

Peripheral neuropathy refers to the conditions that result when nerves that carry messages to and from the brain and spinal cord from and to the rest of the body are damaged or diseased.

Rheumatoid arthritis

Rheumatoid arthritis is an autoimmune disease that causes chronic joint inflammation.

Schizophrenia

Schizophrenia is a chronic and severe mental disorder that affects how a person thinks, feels, and behaves.

Sjogren's syndrome

Sjogren's (SHOW-grins) syndrome is a disorder of the immune system identified by its two most common symptoms – dry eyes and a dry mouth.

Systemic lupus erythematosus

Systemic lupus erythematosus (SLE) is a chronic disease that causes inflammation in connective tissues, such as cartilage and the lining of blood vessels, which provide strength and flexibility to structures throughout the body.

Tourette's syndrome

Tourette's syndrome (TS) is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics.

Uveitis

Uveitis is a general term describing a group of inflammatory diseases that produces swelling and destroys eye tissues.

Citations/Sources

- [1] Živković, S., Autoimmune Neurologic Disorders. *Current Neuropharmacology* 2011, 9 (3), 399.
- [2] Rousset, B.; Bernier-Valentin, F.; Poncet, C.; Orgiazzi, J.; Madec, A. M.; Monier, J. C.; Mornex, R., Anti-tubulin antibodies in autoimmune thyroid disorders. *Clin Exp Immunol* 1983, 52 (2), 325-32.
- [3] Hedegaard, C. J.; Chen, N.; Sellebjerg, F.; Sørensen, P. S.; Leslie, R. G. Q.; Bendtzen, K.; Nielsen, C. H., Autoantibodies to myelin basic protein (MBP) in healthy individuals and in patients with multiple sclerosis: a role in regulating cytokine responses to MBP. *Immunology* 2009, 128 (1 Pt 2), e451-61.
- [4] Nakashima, I., Anti-myelin oligodendrocyte glycoprotein antibody in demyelinating diseases. *Clinical and Experimental Neuroimmunology* 2015, 6 (S1), 59-63.
- [5] Simons, M., Overexpression of the myelin proteolipid protein leads to accumulation of cholesterol and proteolipid protein in endosomes/lysosomes: implications for Pelizaeus-Merzbacher disease. 2002, 157 (2), 327-36.
- [6] Warren, K. G.; Catz, I., Relative frequency of autoantibodies to myelin basic protein and proteolipid protein in optic neuritis and multiple sclerosis cerebrospinal fluid. *J Neurol Sci* 1994, 121 (1), 66-73.
- [7] Sellebjerg, F. T.; Frederiksen, J. L.; Olsson, T., Anti-myelin basic protein and anti-proteolipid protein antibody-secreting cells in the cerebrospinal fluid of patients with acute optic neuritis. *Archives of neurology* 1994, 51 (10), 1032-6.
- [8] Yamasaki, R., Anti-neurofascin antibody in combined central and peripheral demyelination. *Clinical and Experimental Neuroimmunology* 2013, 4 (s1), 68-75.
- [9] Ogata, H.; Yamasaki, R., Anti-neurofascin 155 antibody-related neuropathy. *Clinical and Experimental Neuroimmunology* 2018, 9 (1), 54-64.
- [10] Mathey, E. K.; Derfuss, T.; Storch, M. K.; Williams, K. R.; Hales, K.; Woolley, D. R.; Al-Hayani, A.; Davies, S. N.; Rasband, M. N.; Olsson, T.; Moldenhauer, A.; Velhin, S.; Hohlfeld, R.; Meinel, E.; Linington, C., Neurofascin as a novel target for autoantibody-mediated axonal injury. *The Journal of Experimental Medicine* 2007, 204 (10), 2363-2372.
- [11] Kawamura, N.; Yamasaki, R.; Yonekawa, T.; Matsushita, T.; Kusunoki, S.; Nagayama, S.; Fukuda, Y.; Ogata, H.; Matsuse, D.; Murai, H.; Kira, J.-i., Anti-neurofascin antibody in patients with combined central and peripheral demyelination. *Neurology* 2013, 81 (8), 714-722.
- [12] Svahn, J.; Petiot, P.; Antoine, J.-C.; Vial, C.; Delmont, E.; Viala, K.; Steck, A. J.; Magot, A.; Cauquil, C.; Zarea, A.; Echaniz-Laguna, A.; Iancu Ferfoggia, R.; Gueguen, A.; Magy, L.; Léger, J.-M.; Kuntzer, T.; Ferraud, K.; Lacour, A.; Camdessanché, J.-P., Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features. *Journal of Neurology, Neurosurgery & Psychiatry* 2017.
- [13] Bargerstock, E.; Puvenna, V.; Iffland, P.; Falcone, T.; Hossain, M.; Vetter, S.; Man, S.; Dickstein, L.; Marchi, N.; Ghosh, C.; Carvalho-Tavares, J.; Janigro, D., Is peripheral immunity regulated by blood-brain barrier permeability changes? *PLoS One* 2014, 9 (7), e101477.
- [14] Zhang, Z.; Zoltewicz, J. S.; Mondello, S.; Newsom, K. J.; Yang, Z.; Yang, B.; Kobeissy, F.; Guingab, J.; Glushakova, O.; Robicsek, S.; Heaton, S.; Buki, A.; Hannay, J.; Gold, M. S.; Rubenstein, R.; Lu, X. C.; Dave, J. R.; Schmid, K.; Tortella, F.; Robertson, C. S.; Wang, K. K., Human traumatic brain injury induces autoantibody response against glial fibrillary acidic protein and its breakdown products. *PLoS One* 2014, 9 (3), e92698.
- [15] Lemke, M. R.; Glatzel, M.; Henneberg, A. E., Antimicroglia antibodies in sera of Alzheimer's disease patients. *Biol Psychiatry* 1999, 45 (4), 508-11.
- [16] Shimizu, F.; Schaller, K. L.; Owens, G. P.; Cotleur, A. C.; Kellner, D.; Takeshita, Y.; Obermeier, B.; Kryzer, T. J.; Sano, Y.; Kanda, T.; Lennon, V. A.; Ransohoff, R. M.; Bennett, J. L., Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica. *Science Translational Medicine* 2017, 9 (397).
- [17] Vaishnav, R. A.; Liu, R.; Chapman, J.; Roberts, A. M.; Ye, H.; Rebolledo-Mendez, J. D.; Tabira, T.; Fitzpatrick, A. H.; Achiron, A.; Running, M. P.; Friedland, R. P., Aquaporin 4 Molecular Mimicry and Implications for Neuromyelitis Optica. *J Neuroimmunol* 2013, 260 (0), 92-8.
- [18] Antoine, J.-C.; Honnorat, J.; Camdessanché, J.-P.; Magistris, M.; Absi, L.; Mosnier, J.-F.; Petiot, P.; Kopp, N.; Michel, D., Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. *Annals of Neurology* 2001, 49 (2), 214-221.
- [19] Yang, Y.; Shum, H.; Haigentz, M.; Mariuma, E.; Suhrland, M.; Maleki, S.; Acevedo, N.; Gulko, E.; Farinhas, J.; Welch, M., Anti-Ri antibody associated paraneoplastic brainstem and cerebellar dysfunction as the presenting sign of small cell lung carcinoma (P4.237). *Neurology* 2015, 84 (14 Supplement).
- [20] Lee, J. J.; Koh, K. M.; Kim, U. S., The Anti-Acetylcholine Receptor Antibody Test in Suspected Ocular Myasthenia Gravis. *Journal of Ophthalmology* 2014, 2014, 4.
- [21] Konecny, I.; Cossins, J.; Vincent, A., The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis. *Journal of Anatomy* 2014, 224 (1), 29-35.
- [22] Hill, M., THE NEUROMUSCULAR JUNCTION DISORDERS. *Journal of Neurology, Neurosurgery & Psychiatry* 2003, 74 (suppl 2), ii32-ii37.
- [23] Meriggioli, M. N.; Sanders, D. B., Muscle autoantibodies in myasthenia gravis: beyond diagnosis? *Expert Rev Clin Immunol* 2012, 8 (5), 427-38.

Citations/Sources

- [24] Hadjivassiliou, M.; Boscolo, S.; Tongiorgi, E.; Grunewald, R. A.; Sharrack, B.; Sanders, D. S.; Woodroffe, N.; Davies-Jones, G. A., Cerebellar ataxia as a possible organ-specific autoimmune disease. *Mov Disord* 2008, 23 (10), 1370-7.
- [25] Goines, P., AUTOANTIBODIES TO CEREBELLUM IN CHILDREN WITH AUTISM ASSOCIATE WITH BEHAVIOR. 2011, 25 (3), 514-23.
- [26] Venkatraman, A.; Opal, P., Paraneoplastic cerebellar degeneration with anti-Yo antibodies – a review. *Ann Clin Transl Neurol* 2016, 3 (8), 655-63.
- [27] Rygiel, K., Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies. *Indian Journal of Pharmacology* 2016, 48 (6), 629-36.
- [28] Wu, J.; Li, L., Autoantibodies in Alzheimer's disease: potential biomarkers, pathogenic roles, and therapeutic implications. *Journal of Biomedical Research* 2016, 30 (5), 361-72.
- [29] Levite, M., GLUTAMATE RECEPTOR ANTIBODIES IN NEUROLOGICAL DISEASES: Anti-AMPA-GluR3 antibodies, Anti-NMDA-NR1 antibodies, Anti-NMDA-NR2A/B antibodies, Anti-mGluR1 antibodies or Anti-mGluR5 antibodies are present in subpopulations of patients with either: Epilepsy, Encephalitis, Cerebellar Ataxia, Systemic Lupus Erythematosus (SLE) and Neuropsychiatric SLE, Sjogren's syndrome, Schizophrenia, Mania or Stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate Blood Brain Barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and Ataxia in animal models, and can be removed or silenced in some patients by immunotherapy. *Journal of Neural Transmission* 2014, 121 (8), 1029-1075.
- [30] Dale, R. C.; Merheb, V.; Pillai, S.; Wang, D.; Cantrill, L.; Murphy, T. K.; Ben-Pazi, H.; Varadkar, S.; Aumann, T. D.; Horne, M. K.; Church, A. J.; Fath, T.; Brilot, F., Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders. *Brain* 2012, 135 (Pt 11), 3453-68.
- [31] Platt, M. P.; Agalliu, D.; Cutforth, T., Hello from the Other Side: How Autoantibodies Circumvent the Blood-Brain Barrier in Autoimmune Encephalitis. *Front Immunol* 2017, 8.
- [32] Brudek, T.; Winge, K.; Folke, J.; Christensen, S.; Fog, K.; Pakkenberg, B.; Pedersen, L. Ø., Autoimmune antibody decline in Parkinson's disease and Multiple System Atrophy; a step towards immunotherapeutic strategies. *Molecular Neurodegeneration* 2017, 12 (1), 44.
- [33] Wallukat, G.; Pruss, H.; Muller, J.; Schimke, I., Correction: Functional autoantibodies in patients with different forms of dementia. *PLoS One* 2018, 13 (8), e0203253.
- [34] Singh, M.; Prakash, A., Possible role of endothelin receptor against hyperhomocysteinemia and beta-amyloid induced AD type of vascular dementia in rats. *Brain research bulletin* 2017, 133, 31-41.
- [35] Kayser, M. S.; Dalmau, J., Anti-NMDA Receptor Encephalitis in Psychiatry. *Current psychiatry reviews* 2011, 7 (3), 189-93.
- [36] Husebye, E. S.; Sthoeger, Z. M.; Dayan, M.; Zinger, H.; Elbirt, D.; Levite, M.; Mozes, E., Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in sera of patients with systemic lupus erythematosus. *Annals of the Rheumatic Diseases* 2005, 64 (8), 1210-1213.
- [37] Chang, P. K.; Verbich, D.; McKinney, R. A., AMPA receptors as drug targets in neurological disease--advantages, caveats, and future outlook. *The European journal of neuroscience* 2012, 35 (12), 1908-16.
- [38] Ben-Pazi, H.; Stoner, J. A.; Cunningham, M. W., Dopamine receptor autoantibodies correlate with symptoms in Sydenham's chorea. *PLoS One* 2013, 8 (9), e73516.
- [39] Kleppner, S. R.; Tobin, A. J., GABA signalling: therapeutic targets for epilepsy, Parkinson's disease and Huntington's disease. *Expert opinion on therapeutic targets* 2001, 5 (2), 219-39.
- [40] Boronat, A.; Gelfand, J. M.; Gresa-Arribas, N.; Jeong, H. Y.; Walsh, M.; Roberts, K.; Martinez-Hernandez, E.; Rosenfeld, M. R.; Balice-Gordon, R.; Graus, F.; Rudy, B.; Dalmau, J., Encephalitis and antibodies to DPPX, a subunit of Kv4.2 potassium channels. *Ann Neurol* 2013, 73 (1), 120-8.
- [41] Carvajal-González, A.; Leite, M. I.; Waters, P.; Woodhall, M.; Coutinho, E.; Balint, B.; Lang, B.; Pettingill, P.; Carr, A.; Sheerin, U. M.; Press, R.; Lunn, M. P.; Lim, M.; Maddison, P.; Meinck, H.; Vandenberghe, W.; Vincent, A., Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. *Brain* 2014, 137 (8), 2178-92.
- [42] Gresa-Arribas, N.; Planaguma, J.; Petit-Pedrol, M.; Kawachi, I.; Katada, S.; Glaser, C. A.; Simabukuro, M. M.; Armangue, T.; Martinez-Hernandez, E.; Graus, F.; Dalmau, J., Human neurexin-3alpha antibodies associate with encephalitis and alter synapse development. *Neurology* 2016, 86 (24), 2235-42.
- [43] Joubert, B.; Saint-Martin, M.; Noraz, N.; Picard, G.; Rogemond, V.; Ducray, F.; Desestret, V.; Psimaras, D.; Delattre, J. Y.; Antoine, J. C.; Honnorat, J., Characterization of a Subtype of Autoimmune Encephalitis With Anti-Contactin-Associated Protein-like 2 Antibodies in the Cerebrospinal Fluid, Prominent Limbic Symptoms, and Seizures. *JAMA neurology* 2016, 73 (9), 1115-24.
- [44] Mayasi, Y.; Takhtani, D.; Garg, N., Leucine-rich glioma-inactivated protein 1 antibody encephalitis: A case report. *Neurology® Neuroimmunology & Neuroinflammation* 2014, 1 (4).

Citations/Sources

- [45] Ortega Suero, G.; Sola-Valls, N.; Escudero, D.; Saiz, A.; Graus, F., Anti-Ma and anti-Ma2-associated paraneoplastic neurological syndromes. *Neurologia (Barcelona, Spain)* 2018, 33 (1), 18-27.
- [46] Eimer, W. A.; Vijaya Kumar, D. K.; Shanmugam, N. K. N.; Rodriguez, A. S.; Mitchell, T.; Washicosky, K. J.; György, B.; Breakefield, X. O.; Tanzi, R. E.; Moir, R. D., Alzheimer's Disease-Associated β -Amyloid Is Rapidly Seeded by Herpesviridae to Protect against Brain Infection. *Neuron* 2018, 99 (1), 56-63.e3.
- [47] Berger, J. R.; Houff, S., Neurological complications of herpes simplex virus type 2 infection. *Archives of neurology* 2008, 65 (5), 596-600.
- [48] Martelius, T.; Lappalainen, M.; Palomäki, M.; Anttila, V.-J., Clinical characteristics of patients with Epstein Barr virus in cerebrospinal fluid. *BMC Infectious Diseases* 2011, 11 (1), 281.
- [49] Munger, K. L.; Levin, L. I.; O'Reilly, E. J.; Falk, K. I.; Ascherio, A., Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel. *Multiple sclerosis (Houndmills, Basingstoke, England)* 2011, 17 (10), 1185-93.
- [50] Ang, C. W.; Jacobs, B. C.; Brandenburg, A. H.; Laman, J. D.; van der Meché, F. G. A.; Osterhaus, A. D. M. E.; van Doorn, P. A., Cross-reactive antibodies against GM2 and CMV-infected fibroblasts in Guillain-Barré syndrome. *Neurology* 2000, 54 (7), 1453-1458.
- [51] Khalili-Shirazi, A.; Gregson, N.; Gray, I.; Rees, J.; Winer, J.; Hughes, R., Antiganglioside antibodies in Guillain-Barré syndrome after a recent cytomegalovirus infection. *Journal of Neurology, Neurosurgery & Psychiatry* 1999, 66 (3), 376-379.
- [52] Tejada-Simon, M. V.; Zang, Y. C. Q.; Hong, J.; Rivera, V. M.; Zhang, J. Z., Cross-reactivity with myelin basic protein and human herpesvirus-6 in multiple sclerosis. *Annals of Neurology* 2003, 53 (2), 189-197.
- [53] Readhead, B.; Haure-Mirande, J. V.; Funk, C. C.; Richards, M. A.; Shannon, P.; Haroutunian, V.; Sano, M.; Liang, W. S.; Beckmann, N. D.; Price, N. D.; Reiman, E. M.; Schadt, E. E.; Ehrlich, M. E.; Gandy, S.; Dudley, J. T., Multiscale Analysis of Independent Alzheimer's Cohorts Finds Disruption of Molecular, Genetic, and Clinical Networks by Human Herpesvirus. *Neuron* 2018, 99 (1), 64-82.e7.
- [54] Cunningham, M. W., Rheumatic Fever, Autoimmunity and Molecular Mimicry: The Streptococcal Connection. *Int Rev Immunol* 2014, 33 (4), 314-29.
- [55] Liu, C. C.; Kanekiyo, T.; Xu, H.; Bu, G., Apolipoprotein E and Alzheimer disease: risk, mechanisms, and therapy. *Nature reviews. Neurology* 2013, 9 (2), 106-18.
- [56] Fasano, A., Intestinal permeability and its regulation by zonulin: diagnostic and therapeutic implications. *Clin Gastroenterol Hepatol* 2012, 10 (10), 1096-100.
- [57] Caito, S.; Aschner, M., Neurotoxicity of metals. *Handbook of clinical neurology* 2015, 131, 169-89.
- [58] Reinhard, M. J.; Satz, P.; Scaglione, C. A.; D'Elia, L. F.; Rassovsky, Y.; Arita, A. A.; Hinkin, C. H.; Thrasher, D.; Ordog, G., Neuropsychological exploration of alleged mold neurotoxicity. *Arch Clin Neuropsychol* 2007, 22 (4), 533-43.
- [59] Bredesen, D. E., Reversal of cognitive decline: A novel therapeutic program. *Aging (Albany NY)* 2014, 6 (9), 707-17.
- [60] Dye, R. V.; Miller, K. J.; Singer, E. J.; Levine, A. J., Hormone Replacement Therapy and Risk for Neurodegenerative Diseases. *International Journal of Alzheimer's Disease* 2012, 2012.
- [61] Carmeli, E., Physical Therapy for Neurological Conditions in Geriatric Populations. *Frontiers in Public Health* 2017, 5.
- [62] Sijobert, B.; Azevedo-Coste, C.; Andreu, D.; Verna, C.; Geny, C., Effects of Sensitive Electrical Stimulation Based Cueing in Parkinson's Disease: A Preliminary Study. *European Journal of Translational Myology* 2016, 26 (2).
- [63] Aldehri, M.; Temel, Y.; Alnaami, I.; Jahanshahi, A.; Heschem, S., Deep brain stimulation for Alzheimer's Disease: An update. *Surgical Neurology International* 2018, 9.
- [64] Muhammad, C. M.; Moonaz, S. H., Yoga as Therapy for Neurodegenerative Disorders: A Case Report of Therapeutic Yoga for Adrenomyeloneuropathy. *Integrative Medicine: A Clinician's Journal* 2014, 13 (3), 33-9.
- [65] Asakawa, T.; Xia, Y., Can Acupuncture Treat Alzheimer's Disease and Other Neurodegenerative Disorders? In *Current Research in Acupuncture*, Xia, Y.; Ding, G.; Wu, G.-C., Eds. Springer New York: New York, NY, 2013; pp 255-301.
- [66] de Ru, E., The possibilities of using elastic therapeutic (Kinesio) tape in patients with scoliosis. *Scoliosis*. 2014;9(Suppl 1):P12. doi:10.1186/1748-7161-9-S1-P12.
- [67] Douris, P. C.; Cogen, Z. S.; Fields, H. T.; Greco, L. C.; Hasley, M. R.; Machado, C. M.; Romagnuolo, P. M.; Stamboulis, G.; DiFrancisco-Donoghue, J., THE EFFECTS OF BLOOD FLOW RESTRICTION TRAINING ON FUNCTIONAL IMPROVEMENTS IN AN ACTIVE SINGLE SUBJECT WITH PARKINSON DISEASE. *International Journal of Sports Physical Therapy* 2018, 13 (2), 247-54.
- [68] Dommerholt, J., Dry needling – peripheral and central considerations. *J Man Manip Ther* 2011, 19 (4), 223-7.
- [69] Laukkanen, T.; Kunutsor, S.; Kauhanen, J.; Laukkanen, J. A., Sauna bathing is inversely associated with dementia and Alzheimer's disease in middle-aged Finnish men. *Age Ageing* 2017, 46 (2), 245-249.
- [70] Scarmeas, N.; Stern, Y.; Tang, M. X.; Mayeux, R.; Luchsinger, J. A., Mediterranean Diet and Risk for Alzheimer's Disease. *Ann Neurol* 2006, 59 (6), 912-21.
- [71] Kerkisick, C.; Willoughby, D., The Antioxidant Role of Glutathione and N-Acetyl-Cysteine Supplements and Exercise-Induced Oxidative Stress. *Journal of the International Society of Sports Nutrition* 2005, 2 (2), 38-44.

Citations/Sources

- [72] Brustolin, S.; Giugliani, R.; Félix, T. M., Genetics of homocysteine metabolism and associated disorders. *Braz J Med Biol Res* 2010, 43 (1), 1-7.
- [73] Stover, P. J., Vitamin B12 and older adults. *Current opinion in clinical nutrition and metabolic care* 2010, 13 (1), 24-7.
- [74] Gomes, M. B.; Negrato, C. A., Alpha-lipoic acid as a pleiotropic compound with potential therapeutic use in diabetes and other chronic diseases. *Diabetology & Metabolic Syndrome* 2014, 6.
- [75] Martin, A.; Youdim, K.; Szprengiel, A.; Shukitt-Hale, B.; Joseph, J., Roles of Vitamins E and C on Neurodegenerative Diseases and Cognitive Performance. *Nutrition Reviews* 2002, 60 (10), 308-326.

Risk and Limitations

Neural Zoomer *Plus* testing has been developed and its performance characteristics determined by Vibrant America LLC and Vibrant Genomics (for ApoE testing), both CLIA certified laboratories and utilizes ISO-13485 developed technology. These assays have not been cleared or approved by the U.S. Food and Drug Administration.

The labs have effective procedures in place to protect against technical and operational problems. However, such problems may still occur. Examples include failure to obtain the result for a specific antigen due to circumstances beyond Vibrant's control. Vibrant may re-test a sample in order to obtain these results but upon re-testing the results may still not be obtained. As with all medical laboratory testing, there is a small chance that the laboratory could report incorrect results. A tested individual may wish to pursue further testing to verify any results.

Tested individuals may find their experience is not consistent with Vibrant's selected peer reviewed scientific research findings of relative improvement for study groups. The science in this area is still developing and many personal health factors affect diet and health. Since subjects in the scientific studies referenced in this report may have had personal health and other factors different from those of tested individuals, results from these studies may not be representative of the results experienced by tested individuals. Further, some recommendations may or may not be attainable, depending on the tested individual's physical ability or other personal health factors.

A limitation of this testing is that many of these scientific studies may have been performed in selected populations only. The interpretations and recommendations are done in the context of these studies, but the results may or may not be relevant to tested individuals of different or mixed ethnicities.

The information in this report is intended for educational purposes only. While every attempt has been made to provide current and accurate information, neither the author nor the publisher can be held accountable for any errors or omissions.

Vibrant Wellness makes no claims as to the diagnostic or therapeutic use of its tests or other informational materials. Vibrant Wellness reports and other information do not constitute medical advice and are not a substitute for professional medical advice. Please consult your healthcare practitioner for questions regarding test results, or before beginning any course of supplementation or dietary changes.